Phase III latanoprost studies in Scandinavia, the United Kingdom and the United States
- 1 February 1997
- journal article
- Published by Elsevier in Survey of Ophthalmology
- Vol. 41, S105-S110
- https://doi.org/10.1016/s0039-6257(97)80016-1
Abstract
No abstract availableKeywords
This publication has 13 references indexed in Scilit:
- The additive intraocular pressure-lowering effect of latanoprost in combined therapy with other ocular hypotensive agentsSurvey of Ophthalmology, 1997
- Prostaglandin-induced iridial pigmentation in primatesSurvey of Ophthalmology, 1997
- Latanoprost, a Prostaglandin Analog, for Glaucoma TherapyOphthalmology, 1996
- Latanoprost administered once daily caused a maintained reduction of intraocular pressure in glaucoma patients treated concomitantly with timolol.British Journal of Ophthalmology, 1995
- Effects of PhXA41, A New Prostaglandin F2α Analog, on Aqueous Humor Dynamics in Human EyesOphthalmology, 1993
- Maintained Intraocular Pressure Reduction With Once-a-Day Application of a New Prostaglandin F2α Analogue (PhXA41)Archives of Ophthalmology (1950), 1993
- Phenyl-substituted prostaglandins: potent and selective antiglaucoma agentsJournal of Medicinal Chemistry, 1993
- Intraocular Pressure Reduction With PhXA34, a New Prostaglandin Analogue, in Patients With Ocular HypertensionArchives of Ophthalmology (1950), 1992
- Prostaglandin F2α increases uveoscleral outflow in the cynomolgus monkeyExperimental Eye Research, 1989
- Increased uveoscleral outflow as a possible mechanism of ocular hypotension caused by prostaglandin F2α-1-isopropylester in the cynomolgus monkeyExperimental Eye Research, 1989